Skip to main content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Profile Image


Christopher Ramsden, M.D.

Lipid Mediators, Inflammation, and Pain Unit

Laboratory of Clinical Investigation
251 Bayview Boulevard Suite 100
Baltimore MD 21224
Office: 410-558-8369
Lab: 410-558-8369

Dr. Ramsden served as Medical Investigator in the Section on Nutritional Neurosciences as a Lieutenant Commander in the Commissioned Corps of the U.S. Public Health Service. He is the Principal Investigator on a the major LMBB SNN dietary randomized controlled trial investigating the clinical and biochemical effects of controlled alterations in dietary omega-6 and omega-3. He is also currently the principal investigator or lead associate investigator on five interdisciplinary randomized controlled trials investigating the clinical and biochemical effects of controlled alterations in dietary omega-6 and omega-3 fatty acids. Four of these trials are in patient populations with chronic pain or psychiatric disorders (episodic migraine, post-traumatic headache, lumbosacral radicular pain, bipolar disease), and another in healthy volunteers. Dr. Ramsden is also investigating the molecular mechanisms linking lipid autacoids and their precursors to inflammatory and nociceptive signaling. Dr. Ramsden is currently developing his research program as a Tenure –Track Investigator at National Institute on Aging as Acting Chief of the Lipid Mediators, Inflammation and Pain Unit with a Joint Clinical Appointment with NIA/NIAAA.

The objectives of the Lipid Mediator, Inflammation, and Pain Unit are: (1) to discover new mediators and mechanisms linking lipids to age-related diseases including chronic pain, cardiovascular and neurodegenerative diseases, and (2) to translate these discoveries into targeted, safe and effective nutrition-based and drug-based treatments. The Unit applies an interdisciplinary, translational approach—comprising randomized controlled trials, non-randomized clinical and postmortem studies, missing data recovery, synthetic and analytical chemistry, animal models, immunohistochemistry, and cellular and ex vivo assays—to achieve these objectives.

Staff Image
  • 1) Ramsden CE, Domenichiello AF, Yuan ZX, Sapio MR, Keyes GS, Mishra SK, Gross JR, Majchrzak-Hong S, Zamora D, Horowitz MS, Davis JM, Sorokin AV, Dey A, LaPaglia DM, Wheeler JJ, Vasko MR, Mehta NN, Mannes AJ, Iadarola MJ (2017)
  • A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch
  • Sci Signal, 10(493)
  • 2) Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR (2016)
  • Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)
  • BMJ, 353:i1246
  • 3) Ramsden CE, Ringel A, Majchrzak-Hong SF, Yang J, Blanchard H, Zamora D, Loewke JD, Rapoport SI, Hibbeln JR, Davis JM, Hammock BD, Taha AY (2016)
  • Dietary linoleic acid-induced alterations in pro- and anti-nociceptive lipid autacoids: Implications for idiopathic pain syndromes?
  • Mol Pain, 12
  • 4) Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR (2013)
  • Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis
  • BMJ, 346:e8707
  • 5) Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, Mann JD (2013)
  • Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial
  • Pain, 154(11):2441-51
View Pubmed Publication